Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ninian N Lang

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Clinical Science (London, England : 1979)|December 9, 2021
Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicityNinian N Lang, Rhian M Touyz
Biochemical Pharmacology|April 6, 2010
Urocortins in heart failureSowmya Venkatasubramanian, David E Newby, Ninian N Lang
The Canadian Journal of Cardiology|March 13, 2016
Vascular Complications of Cancer ChemotherapyAlan C Cameron, Rhian M Touyz, Ninian N Lang
Drugs|September 27, 2016
Drug Treatment of Hypertension: Focus on Vascular HealthAlan C Cameron, Ninian N Lang, Rhian M Touyz
Cardiovascular Therapeutics|June 10, 2010
Vascular PAR-1: activity and antagonismNinian N Lang, Ingibjörg J Guðmundsdóttir, David E Newby
American Journal of Physiology. Heart and Circulatory Physiology|November 7, 2006
Connexin 43 mediates endothelium-derived hyperpolarizing factor-induced vasodilatation in subcutaneous resistance arteries from healthy pregnant womenNinian N Lang, Leonid Luksha, David E Newby, et al.
Clinical Science (London, England : 1979)|September 29, 2020
Vascular toxicity associated with anti-angiogenic drugsKarla B Neves, Augusto C Montezano, Ninian N Lang, et al.
Cardiovascular Research|August 25, 2022
Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapiesSanne de Wit, Claire Glen, Rudolf A de Boer, et al.
Biomarkers in Medicine|September 17, 2014
Emerging biomarkers for heart failure: an updateJonathan R Dalzell, Jane A Cannon, Colette E Jackson, et al.
Frontiers in Cardiovascular Medicine|December 30, 2022
Cardiac geometry, as assessed by cardiac magnetic resonance, can differentiate subtypes of chronic thromboembolic pulmonary vascular diseaseMichael McGettrick, Helen Dormand, Melanie Brewis, et al.
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Clinical Science (London, England : 1979)|December 9, 2021
Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicityNinian N Lang, Rhian M Touyz
Biochemical Pharmacology|April 6, 2010
Urocortins in heart failureSowmya Venkatasubramanian, David E Newby, Ninian N Lang
The Canadian Journal of Cardiology|March 13, 2016
Vascular Complications of Cancer ChemotherapyAlan C Cameron, Rhian M Touyz, Ninian N Lang
Drugs|September 27, 2016
Drug Treatment of Hypertension: Focus on Vascular HealthAlan C Cameron, Ninian N Lang, Rhian M Touyz
Cardiovascular Therapeutics|June 10, 2010
Vascular PAR-1: activity and antagonismNinian N Lang, Ingibjörg J Guðmundsdóttir, David E Newby
American Journal of Physiology. Heart and Circulatory Physiology|November 7, 2006
Connexin 43 mediates endothelium-derived hyperpolarizing factor-induced vasodilatation in subcutaneous resistance arteries from healthy pregnant womenNinian N Lang, Leonid Luksha, David E Newby, et al.
Clinical Science (London, England : 1979)|September 29, 2020
Vascular toxicity associated with anti-angiogenic drugsKarla B Neves, Augusto C Montezano, Ninian N Lang, et al.
Cardiovascular Research|August 25, 2022
Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapiesSanne de Wit, Claire Glen, Rudolf A de Boer, et al.
Biomarkers in Medicine|September 17, 2014
Emerging biomarkers for heart failure: an updateJonathan R Dalzell, Jane A Cannon, Colette E Jackson, et al.
Frontiers in Cardiovascular Medicine|December 30, 2022
Cardiac geometry, as assessed by cardiac magnetic resonance, can differentiate subtypes of chronic thromboembolic pulmonary vascular diseaseMichael McGettrick, Helen Dormand, Melanie Brewis, et al.
Pageof 9